This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
EARLY PROPHYLACTIC use of clotting factors in patients with severe hemophilia is gaining acceptance as a way to prevent the pain, morbidity, and mortality associated with bleeding disorders.
Earlier this year, the National Hemophilia Foundation (NHF), New York, NY, adopted recommendations calling on physicians to consider treating young patients with severe hemophilia with appropriate clotting factors three times a week to prevent painful and crippling bleeding episodes.
For its 46th annual meeting in Dallas, Tex, next week, the foundation has scheduled two symposia on new treatment options—one for patients and their families and one for physicians.
The new recommendations are based on extensive clinical research, conducted primarily in Sweden, that shows that early primary prophylaxis may prevent painful and crippling joint damage as well as disabling or fatal brain hemorrhages, says Marilyn Manco-Johnson, MD, director of the Mountain States Regional Hemophilia Center and associate professor of pediatrics, University of Colorado
Skolnick AA. Hemophilia Foundation Recommends Prophylactic Use of Clotting Factors. JAMA. 1994;272(15):1153–1154. doi:10.1001/jama.1994.03520150019005
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: